The TREAT study was a prospective cohort study nested within a randomized clinical trial to establish ESRD risk and composite of death or ESRD risk models using serum levels of the cardiac biomarkers TnT and NT-pro-BNP in 4038 patients with type 2 diabetes, anemia, and CKD14. This evidence concerns the gene NPPB and anemia.